HCC
151
35
49
41
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.6%
4 terminated out of 151 trials
91.1%
+4.6% vs benchmark
11%
16 trials in Phase 3/4
24%
10 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 41 completed trials
Clinical Trials (151)
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Optimizing Y90 Therapy for Radiation Lobectomy
Multi-analyte Blood Test Clinical Trial
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
CXD101 in Immunotherapy-related Liver Cancer
Y-90 Treatment Response Using Transarterial Radioembolization
Effect of the HCC Liver-Link Intervention
SBRT in HCC With Oligoprogression on First-line Immunotherapy
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
Pembrolizumab in Hepatocellular Carcinoma
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
Cabozantinib in Hepatocellular Carcinoma
REGULUS: MRI-guided Adaptive SABR for Liver Cancers